Voyager Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Voyager Therapeutics hat ein Gesamteigenkapital von $335.4M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $436.2M bzw. $100.8M.

Wichtige Informationen

0%

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgradn/a
BargeldUS$371.02m
EigenkapitalUS$335.42m
GesamtverbindlichkeitenUS$100.81m
GesamtvermögenUS$436.23m

Jüngste Berichte zur Finanzlage

Recent updates

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17
Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Voyager Therapeutics hires new finance chief

Sep 07

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Aug 04

Looking Back In On Voyager Therapeutics

Jun 08

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12
Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Voyager Does A Reboot After First Generation Failures

Mar 25

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Feb 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Voyager Therapeutics: Another Year, Another Deal

Nov 21

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VYGRDie kurzfristigen Aktiva des Unternehmens ($381.6M) übersteigen seine kurzfristigen Passiva ($40.1M).

Langfristige Verbindlichkeiten: VYGRDie kurzfristigen Vermögenswerte des Unternehmens ($381.6M) übersteigen seine langfristigen Verbindlichkeiten ($60.7M).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VYGR ist schuldenfrei.

Schulden abbauen: VYGR hatte vor 5 Jahren keine Schulden.

Schuldendeckung: VYGR hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: VYGR hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.


Bilanz


Entdecken Sie finanziell stabile Unternehmen